Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)
|
November 28, 2008
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors
Natalie Minkovsky, Alan Berezov
Molecular Systems Biology
|
October 4, 2006
Towards comprehensive characterization of HER2 overexpression
Alan Berezov, Mark I Greene
Methods (San Diego, Calif.)
|
June 24, 2008
Modulation of biomolecular interactions with complex-binding small molecules
Zheng Cai, Mark I Greene, Alan Berezov
Immunologic Research
|
July 15, 2003
Structure-based approaches to inhibition of erbB receptors with peptide mimetics
Alan Berezov, Mark I Greene, Ramachandran Murali
Journal of Immunology (Baltimore, Md. : 1950)
|
January 5, 2007
Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors
Keiji Furuuchi, Alan Berezov, Toru Kumagai, et al.
The Protein Journal
|
December 6, 2005
Electron paramagnetic resonance and fluorescence studies of the conformation of aspartate aminotransferase bound to GroEL
Alan Berezov, Megan J McNeill, Ana Iriarte, et al.
International Immunopharmacology
|
June 23, 2009
Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target
Zhaocai Zhou, Xiaomin Song, Alan Berezov, et al.
Oncogene
|
February 13, 2002
HER2/Neu: mechanisms of dimerization/oligomerization
Patrick J Brennan, Toru Kumagai, Alan Berezov, et al.
DNA and Cell Biology
|
June 9, 2005
HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand
Veronique Guillemard, Hinyu N Nedev, Alan Berezov, et al.
The Journal of Biological Chemistry
|
May 16, 2002
Disabling receptor ensembles with rationally designed interface peptidomimetics
Alan Berezov, Jinqiu Chen, Qingdu Liu, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Current Opinion in Investigational Drugs (London, England : 2000)
|
November 28, 2008
BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors
Natalie Minkovsky, Alan Berezov
Molecular Systems Biology
|
October 4, 2006
Towards comprehensive characterization of HER2 overexpression
Alan Berezov, Mark I Greene
Methods (San Diego, Calif.)
|
June 24, 2008
Modulation of biomolecular interactions with complex-binding small molecules
Zheng Cai, Mark I Greene, Alan Berezov
Immunologic Research
|
July 15, 2003
Structure-based approaches to inhibition of erbB receptors with peptide mimetics
Alan Berezov, Mark I Greene, Ramachandran Murali
Journal of Immunology (Baltimore, Md. : 1950)
|
January 5, 2007
Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors
Keiji Furuuchi, Alan Berezov, Toru Kumagai, et al.
The Protein Journal
|
December 6, 2005
Electron paramagnetic resonance and fluorescence studies of the conformation of aspartate aminotransferase bound to GroEL
Alan Berezov, Megan J McNeill, Ana Iriarte, et al.
International Immunopharmacology
|
June 23, 2009
Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target
Zhaocai Zhou, Xiaomin Song, Alan Berezov, et al.
Oncogene
|
February 13, 2002
HER2/Neu: mechanisms of dimerization/oligomerization
Patrick J Brennan, Toru Kumagai, Alan Berezov, et al.
DNA and Cell Biology
|
June 9, 2005
HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand
Veronique Guillemard, Hinyu N Nedev, Alan Berezov, et al.
The Journal of Biological Chemistry
|
May 16, 2002
Disabling receptor ensembles with rationally designed interface peptidomimetics
Alan Berezov, Jinqiu Chen, Qingdu Liu, et al.
Page
of 3